<DOC>
	<DOC>NCT01753323</DOC>
	<brief_summary>This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400 mg/day (Part 1) and single dosing with KAF156 at 800mg (Part 2)</brief_summary>
	<brief_title>Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria, Vivax</mesh_term>
	<criteria>Male and female patients aged 20 to 60 years;Presence of monoinfection of P. falciparum or P. vivax; Weight between 40 kg to 90 kg. Patients with signs and symptoms of severe/complicated malaria Infection with more than one parasite species Women of childbearing potential; pregnant or nursing women Those who have taken any antimalarial treatment in the preceding 14 days or other investigational drugs within 30 days or 5 halflives</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>acute malaria, KAF156</keyword>
</DOC>